Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum
James McCarthy, Azrin N. Abd‐Rahman, Katharine A. Collins, Louise Marquart, Paul Griffin, Anne Kümmel, Aline Fuchs, Cornelis Winnips, Vishal Mishra, Katalin Csermak-Renner, Jay Prakash Jain, Preetam Gandhi
Abstract
The spiroindolone cipargamin, a new antimalarial compound that inhibits Plasmodium ATP4, is currently in clinical development. This study aimed to characterize the antimalarial activity of cipargamin in healthy volunteers experimentally infected with blood-stage Plasmodium falciparum .
Topics & Concepts
Plasmodium falciparumMalariaPlasmodium (life cycle)BiologyParasitemiaVirologyMedicineImmunologyPharmacologyParasite hostingComputer scienceWorld Wide WebMalaria Research and ControlDrug-Induced Hepatotoxicity and ProtectionDrug Transport and Resistance Mechanisms